viral
subunit
vaccin
often
contain
immunodomin
nonneutr
epitop
divert
host
immun
respons
epitop
elimin
vaccin
design
reliabl
method
evalu
epitop
capac
elicit
neutral
immun
respons
introduc
new
concept
neutral
immunogen
index
nii
evalu
epitop
neutral
immunogen
determin
nii
mask
epitop
glycan
probe
assess
epitop
contribut
vaccin
overal
neutral
immunogen
proofofconcept
measur
nii
differ
epitop
immunogen
compris
receptorbind
domain
mer
coronaviru
merscov
design
variant
form
vaccin
mask
epitop
neg
nii
score
engin
vaccin
demonstr
significantli
enhanc
efficaci
protect
transgen
mice
lethal
merscov
challeng
studi
may
guid
ration
design
highli
effect
subunit
vaccin
combat
merscov
lifethreaten
virus
major
goal
viral
subunit
vaccin
develop
ration
design
immunogen
elicit
strong
neutral
immun
respons
host
receptorbind
domain
rbd
viru
surfac
spike
protein
prime
candid
subunit
vaccin
design
contain
epitop
trigger
strong
immun
respons
addit
viral
rbd
play
essenti
role
viral
infect
cycl
bind
host
receptor
viral
attach
thu
part
host
immun
respons
elicit
viral
rbd
target
receptorbind
region
therebi
neutral
viral
entri
host
cell
howev
two
problem
potenti
hinder
develop
viral
rbd
subunit
vaccin
first
virus
evad
host
immun
respons
elicit
spike
rbdbase
vaccin
one
immun
evas
mechan
virus
use
immunodomin
nonneutr
epitop
rbd
divert
host
immun
respons
thoroughli
illustr
case
hiv
receptorbind
subunit
ref
second
taken
context
fulllength
spike
protein
recombin
viral
rbd
vaccin
expos
larg
area
previous
buri
surfac
like
contain
immunodomin
nonneutr
epitop
whether
outcom
viral
evolut
vaccin
design
immunodomin
nonneutr
epitop
viral
rbd
outcompet
epitop
trigger
host
immun
respons
result
immun
respons
target
nonneutr
epitop
neglect
neutral
epitop
viral
rbd
ref
ration
design
viral
subunit
vaccin
aim
focu
immun
respons
neutral
epitop
mask
delet
immunodomin
nonneutr
epitop
critic
gap
subunit
vaccin
design
lack
effect
way
evalu
epitop
neutral
immunogen
capac
elicit
neutral
immun
respons
extens
effort
predict
epitop
immunogen
base
physic
chemic
properti
epitop
howev
method
design
predict
epitop
neutral
immunogen
hold
key
subunit
vaccin
design
although
experiment
method
avail
measur
neutral
immunogen
linear
epitop
take
linear
peptid
context
protein
method
work
conform
epitop
preval
rbdbase
viral
vaccin
find
way
measur
neutral
immunogen
differ
conform
epitop
viral
rbd
tremend
help
ration
design
viral
subunit
vaccin
rbdbase
coronaviru
vaccin
extens
pursu
due
threat
coronavirus
pose
human
health
coronavirus
envelop
positivestrand
rna
virus
sar
coronaviru
sarscov
infect
peopl
fatal
rate
sinc
mer
coronaviru
merscov
infect
peopl
fatal
rate
rbd
sarscov
merscov
contain
core
structur
receptorbind
motif
rbm
core
structur
highli
similar
rbm
markedli
differ
lead
differ
receptor
specif
sarscov
recogn
angiotensinconvert
enzym
wherea
merscov
recogn
dipeptidyl
peptidas
sarscov
merscov
rbd
capabl
elicit
strong
neutral
antibodi
respons
one
hand
enrich
neutral
epitop
rbm
highyield
express
recombin
protein
coronaviru
rbd
promis
subunit
vaccin
candid
moreov
rel
simpl
structur
compar
intact
spike
protein
coronaviru
rbd
provid
excel
model
system
structurebas
subunit
vaccin
design
hand
recent
determin
cryoem
structur
coronaviru
spike
protein
reveal
wherea
rbm
coronaviru
rbd
access
larg
surfac
area
rbd
core
structur
buri
fulllength
spike
protein
supplementari
fig
thu
previous
buri
area
surfac
rbd
core
becom
expos
recombin
rbd
vaccin
like
contain
immunodomin
nonneutr
epitop
divert
host
immun
respons
therefor
coronaviru
rbd
hold
promis
present
challeng
vaccin
develop
critic
evalu
neutral
immunogen
differ
epitop
coronaviru
rbd
immunodomin
neutral
nonneutr
epitop
preserv
elimin
respect
studi
introduc
novel
concept
neutral
immunogen
index
nii
evalu
neutral
immunogen
differ
epitop
viral
subunit
vaccin
proofofconcept
use
nii
tool
identifi
epitop
differ
neutral
immunogen
merscovrbdbas
vaccin
furthermor
success
appli
tool
significantli
enhanc
efficaci
merscov
rbd
vaccin
protect
mice
lethal
merscov
challeng
studi
fill
critic
gap
subunit
vaccin
design
facilit
ration
design
subunit
vaccin
merscov
lifethreaten
virus
evalu
neutral
immunogen
specif
epitop
viral
rbd
vaccin
either
delet
mask
epitop
measur
correspond
chang
vaccin
capac
elicit
neutral
immun
respons
alanin
scan
vaccinesurfac
residu
like
lead
chang
vaccin
overal
immunogen
subtl
measur
use
current
avail
experiment
method
delet
whole
epitop
may
disturb
tertiari
structur
viral
rbd
instead
studi
chose
mask
epitop
interest
use
hostcellderiv
glycan
probe
approach
effect
conveni
glycan
probe
impos
steric
interfer
access
antibodi
immun
cell
epitop
also
glycan
probe
unlik
interfer
fold
solubl
rbd
place
glycan
probe
epitop
introduc
nlink
glycosyl
motif
asparaginexthreonin
x
amino
acid
prolin
onto
differ
epitop
viral
rbd
vaccin
use
sitedirect
mutagenesi
proofofconcept
chose
studi
sever
epitop
merscov
rbd
vaccin
fctag
rbd
fragment
contain
residu
select
studi
previous
show
fragment
stabl
effect
vaccin
candid
four
distinct
epitop
merscov
rbd
fragment
select
base
locat
rbd
surfac
possibl
function
role
receptor
bind
locat
protrud
loop
receptorbind
motif
rbm
region
ii
locat
bstrand
rbm
region
iii
locat
bstrand
core
region
iv
locat
protrud
loop
core
region
fig
b
basi
threedimension
protrus
index
map
supplementari
fig
epitop
contain
high
protrus
index
wherea
epitop
contain
low
protrus
index
introduc
glycan
probe
onto
four
epitop
merscov
rbd
end
introduc
singl
mutat
pair
alreadi
exist
respect
gener
three
nlink
glycosyl
site
also
introduc
doubl
mutat
gener
fourth
nlink
glycosyl
site
glycosyl
site
locat
individu
merscov
rbd
fragment
express
purifi
four
mutant
rbd
mammalian
cell
supplementari
fig
test
whether
four
epitop
merscov
rbd
actual
glycosyl
perform
sd
gel
electrophoresi
mass
spectrometri
compar
wild
type
rbd
mutant
rbd
exhibit
slower
electrophoret
mobil
gel
consist
addit
glycosyl
supplementari
fig
mass
spectrometri
reveal
molecular
weight
mutant
rbd
kda
larger
wild
type
rbd
also
consist
introduc
glycan
probe
mutant
rbd
supplementari
fig
purifi
mutant
rbd
sampl
visibl
presenc
unglycosyl
rbd
sd
gel
mass
spectrometri
spectrum
supplementari
fig
thu
four
epitop
merscov
rbd
success
glycosyl
understand
correl
epitop
role
receptor
bind
potenti
recogn
immun
respons
examin
whether
engin
glycan
probe
merscov
rbd
interf
receptor
bind
end
use
two
altern
approach
one
approach
alphascreen
assay
analys
interact
recombin
rbd
recombin
human
solut
fig
approach
fluorescenceactiv
cell
sort
fac
examin
interact
recombin
rbd
human
express
cellsurfac
fig
result
assay
reveal
glycan
probe
locat
residu
reduc
bind
rbd
glycan
probe
locat
residu
reduc
bind
rbd
even
one
locat
residu
impact
bind
structur
analysi
interact
suggest
glycan
probe
locat
residu
would
seriou
steric
clash
bind
wherea
glycan
probe
locat
residu
would
partial
steric
interfer
bind
fig
glycan
probe
locat
residu
would
far
away
receptorbind
region
impact
bind
henc
biochem
structur
analys
similarli
elucid
role
glycan
probe
bind
rbd
understand
epitop
potenti
interact
neutral
monoclon
antibodi
mab
analys
engin
glycan
probe
interf
bind
rbd
differ
neutral
mab
access
four
human
mab
mab
previous
shown
highli
potent
neutral
merscov
infect
human
cell
elisa
rbd
mab
demonstr
glycan
probe
locat
residu
abolish
bind
rbd
fig
reduc
bind
rbd
fig
c
signific
impact
bind
rbd
fig
contrast
glycan
probe
locat
three
residu
interfer
bind
rbd
mab
bind
site
rbd
mab
previous
character
mutagenesi
andor
structur
studi
three
four
mab
bind
near
epitop
contain
wherea
mab
bind
away
epitop
contain
fig
overal
among
four
select
epitop
epitop
contain
play
import
role
bind
neutral
mab
consequ
glycan
probe
cover
epitop
interf
bind
neutral
mab
studi
thu
far
character
structur
featur
receptor
bind
neutral
mab
bind
four
select
rbd
epitop
use
glycan
probe
strategi
glycan
probe
introduc
one
rbd
epitop
interf
bind
mab
interact
specif
epitop
impact
bind
mab
distant
epitop
observ
suggest
glycan
probe
shield
epitop
glycan
probe
attach
affect
structur
antigen
site
consist
find
obtain
studi
anoth
viral
spike
protein
respiratori
syncyti
rsv
viru
f
protein
evalu
glycan
probe
alter
neutral
immunogen
capac
induc
neutral
immun
respons
merscov
rbd
immun
balbc
mice
four
rbd
contain
one
glycan
probe
immun
schedul
shown
supplementari
fig
sera
collect
mice
immun
rbd
test
merscovneutr
antibodi
compar
wild
type
rbd
vaccin
rbd
contain
glycan
probe
residu
induc
significantli
higher
lower
neutral
antibodi
titr
respect
mous
sera
wherea
rbd
contain
glycan
probe
residu
fail
induc
signific
chang
neutral
antibodi
titr
mous
sera
fig
supplementari
tabl
thu
mask
epitop
contain
led
reduc
neutral
antibodi
titr
immun
mice
demonstr
epitop
made
posit
contribut
vaccin
overal
neutral
immunogen
base
rational
epitop
contain
made
neg
contribut
epitop
contain
made
insignific
contribut
vaccin
overal
neutral
immunogen
experi
repeat
twice
similar
result
obtain
result
provid
qualit
evalu
neutral
immunogen
epitop
quantit
evalu
epitop
neutral
immunogen
introduc
novel
concept
nii
describ
epitop
neutral
immunogen
nii
defin
contribut
epitop
vaccin
overal
neutral
immunogen
determin
mask
epitop
glycan
probe
measur
rel
chang
vaccin
overal
capac
elicit
neutral
antibodi
titr
fig
base
definit
calcul
nii
four
epitop
rbd
fig
supplementari
tabl
epitop
contain
nii
neg
sign
nii
suggest
neg
contribut
epitop
vaccin
overal
neutral
immunogen
valu
nii
implic
mask
epitop
use
glycan
probe
increas
vaccin
overal
neutral
immunogen
three
fold
convers
epitop
contain
nii
suggest
epitop
made
posit
contribut
vaccin
overal
neutral
immunogen
mask
epitop
use
glycan
probe
reduc
vaccin
overal
neutral
immunogen
wild
type
vaccin
therefor
nii
serv
effect
tool
quantit
evalu
neutral
immunogen
epitop
merscov
rbd
vaccin
investig
mask
neg
epitop
led
enhanc
neutral
immunogen
merscov
rbd
vaccin
perform
competit
assay
neutral
mab
mutantrbdinduc
mous
serum
bind
wild
type
merscov
rbd
specif
elisa
carri
neutral
mab
merscov
rbd
presenc
mous
serum
induc
merscov
rbd
fig
b
comparison
mous
serum
induc
wild
type
merscov
rbd
also
includ
two
differ
mab
use
competit
bind
assay
bind
rbm
epitop
contain
ref
bind
rbm
epitop
surround
ref
result
show
serum
induc
rbd
inhibit
mabrbd
bind
significantli
better
serum
induc
wild
type
rbd
reveal
enhanc
neutral
capabl
mous
serum
due
glycosyl
posit
moreov
mous
serum
induc
rbd
demonstr
enhanc
bind
least
two
separ
neutral
epitop
rbm
one
surround
thu
mask
epitop
rbd
core
structur
high
neg
nii
refocus
host
immun
respons
neutral
epitop
rbm
lead
enhanc
neutral
immunogen
rbd
vaccin
ration
design
rbd
vaccin
enhanc
efficaci
prove
highli
effect
merscov
rbd
vaccin
ration
design
base
epitop
neutral
immunogen
investig
efficaci
two
engin
merscov
rbd
vaccin
use
viru
challeng
studi
engin
rbd
vaccin
neg
epitop
epitop
contain
nii
posit
epitop
epitop
contain
nii
mask
respect
glycan
probe
chose
mask
epitop
rather
delet
mutat
residu
alanin
introduc
glycan
conveni
practic
less
disrupt
immunogen
tertiari
structur
wild
type
rbd
vaccin
use
control
anim
model
vaccin
test
lethal
transgen
mous
model
express
human
mice
mice
chosen
analysi
suscept
merscov
also
prevent
diseas
mice
stringent
test
efficaci
immun
schedul
shown
supplementari
fig
briefli
mice
immun
rbd
vaccin
challeng
merscov
surviv
rate
weight
chang
mice
record
efficaci
rbd
vaccin
evalu
base
morbid
mortal
immun
challeng
mice
first
mice
immun
negativeepitopemask
rbd
vaccin
rbd
contain
mutat
surviv
merscov
challeng
surviv
rate
wherea
mice
immun
wild
type
rbd
vaccin
positiveepitopemask
rbd
vaccin
rbd
contain
mutat
demonstr
surviv
rate
respect
merscov
challeng
fig
second
merscov
challeng
caus
weight
loss
mice
immun
negativeepitopemask
rbd
vaccin
led
signific
weight
loss
mice
immun
either
wild
type
rbd
vaccin
positiveepitopemask
rbd
vaccin
fig
experi
repeat
twice
similar
result
obtain
result
reveal
enhanc
efficaci
mab
current
vaccin
design
lack
effect
approach
evalu
neutral
immunogen
epitop
viral
subunit
vaccin
studi
develop
novel
approach
measur
vaccin
epitop
neutral
immunogen
use
merscov
rbd
model
singli
mask
select
epitop
use
hostderiv
glycan
probe
measur
correspond
chang
vaccin
overal
neutral
immunogen
also
develop
method
calcul
nii
select
epitop
epitop
neutral
immunogen
contain
two
part
neutral
capac
immunogen
one
hand
epitop
neutral
capac
determin
physic
overlap
epitop
receptorbind
region
potenti
role
epitop
receptor
bind
hand
epitop
immunogen
determin
immun
self
similar
dissimilar
viral
epitop
hostorigin
epitop
protrus
physic
chemic
properti
epitop
logic
epitop
nii
correl
combin
factor
immun
self
protrus
potenti
overlap
receptorbind
region
complex
natur
nii
unlik
nii
reliabl
predict
softwar
instead
studi
demonstr
nii
experiment
measur
use
glycan
probe
approach
proofofconcept
measur
nii
four
distinct
epitop
merscov
rbd
vaccin
also
character
protrus
index
receptor
bind
monoclon
antibodi
bind
rbd
epitop
mask
glycan
probe
result
reveal
epitop
high
low
protrus
index
tend
nii
high
low
absolut
valu
respect
addit
epitop
within
receptorbind
region
tend
posit
nii
epitop
locat
outsid
receptorbind
region
tend
neg
nii
correl
immun
self
epitop
nii
good
method
evalu
immun
self
conform
epitop
overal
ration
design
viral
subunit
vaccin
epitop
high
posit
nii
preserv
expos
high
neg
nii
elimin
via
delet
mask
inde
studi
identifi
epitop
contain
one
high
neg
nii
merscov
rbd
locat
protrud
loop
away
receptorbind
region
contribut
high
neg
nii
importantli
buri
insid
fulllength
coronaviru
spike
protein
becom
expos
surfac
recombin
merscov
rbd
vaccin
outcom
subunit
vaccin
design
supplementari
fig
overcom
limit
subunit
vaccin
design
newli
expos
epitop
high
neg
nii
need
mask
delet
appli
nii
strategi
vaccin
design
success
enhanc
efficaci
merscov
rbd
vaccin
viru
challeng
studi
mask
strong
neg
epitop
epitop
contain
nii
glycan
probe
engin
vaccin
effect
protect
mice
lethal
merscov
infect
compar
wild
type
rbd
vaccin
mice
immun
engin
rbd
vaccin
show
increas
neutral
antibodi
respons
sera
challeng
merscov
also
demonstr
higher
surviv
rate
less
weight
loss
result
prove
neg
epitop
elimin
vaccin
design
contrast
anoth
engin
vaccin
posit
epitop
mask
epitop
contain
nii
show
reduc
efficaci
viru
challeng
studi
confirm
posit
epitop
preserv
expos
vaccin
design
taken
altogeth
valid
signific
feasibl
nii
strategi
vaccin
design
success
engin
variant
form
merscov
rbd
vaccin
significantli
enhanc
efficaci
overal
studi
contribut
viral
subunit
vaccin
design
follow
way
first
studi
introduc
new
concept
nii
evalu
individu
epitop
contribut
overal
neutral
immunogen
subunit
vaccin
previou
studi
could
evalu
neutral
immunogen
conform
bcell
epitop
domin
coronaviru
rbd
vaccin
second
use
nii
strategi
studi
identifi
immunodomin
nonneutr
epitop
surfac
merscov
rbd
core
structur
result
show
exposur
previous
buri
epitop
viral
subunit
vaccin
pose
challeng
subunit
vaccin
design
concept
although
need
investig
may
critic
develop
mani
viral
rbdbase
vaccin
third
studi
demonstr
mask
immunodomin
nonneutr
epitop
neg
nii
valu
surfac
merscov
rbd
core
structur
shift
host
immun
respons
toward
neutral
epitop
rbm
region
provid
mean
overcom
limit
viral
subunit
vaccin
vaccin
design
previou
studi
show
hypervari
region
hiv
divert
host
immun
respons
mask
region
shift
host
immun
respons
toward
conserv
neutral
epitop
provid
mean
overcom
limit
viral
subunit
vaccin
viral
evolut
fourth
although
nii
strategi
use
current
studi
improv
efficaci
viral
subunit
vaccin
also
potenti
help
epitopebas
vaccin
research
exampl
previou
studi
mask
resurfac
nonneutr
epitop
viral
immunogen
use
engin
immunogen
bait
screen
neutral
sera
monoclon
antibodi
bind
conserv
neutral
epitop
conceiv
nii
strategi
help
identifi
immunodomin
nonneutr
epitop
immunogen
allow
target
epitop
modif
effici
antibodi
screen
final
studi
suggest
threedimension
neutral
immunogen
map
nim
drawn
describ
distribut
epitop
differ
neutral
immunogen
surfac
viral
subunit
vaccin
nim
guid
target
mask
multipl
strong
neg
epitop
enhanc
efficaci
viral
subunit
vaccin
believ
approach
facilit
ration
subunit
vaccin
design
coronavirus
merscov
sarscov
also
lifethreaten
virus
hiv
influenza
viru
ebola
viru
cell
line
human
embryon
kidney
vero
monkey
kidney
cell
obtain
american
type
cultur
collect
human
hepatoma
cell
kindli
provid
dr
charl
rice
rockefel
univers
cell
line
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
mm
lglutamin
unit
ml
penicillin
mg
ml
streptomycin
life
technolog
inc
insect
cell
purchas
life
technolog
inc
cultur
iii
sfm
medium
supplement
unit
ml
penicillin
mg
ml
streptomycin
life
technolog
inc
express
purif
recombin
protein
express
purif
recombin
merscov
rbd
carri
previous
describ
briefli
wild
type
wt
rbd
residu
genbank
access
number
contain
ctermin
human
igg
fc
tag
express
cell
secret
cell
cultur
supernat
purifi
protein
affin
chromatographi
ge
healthcar
mutant
rbd
fragment
contain
engin
glycan
probe
construct
via
sitedirect
mutagenesi
express
purifi
way
wild
type
rbd
express
purif
recombin
human
carri
previous
describ
briefli
human
ectodomain
residu
genbank
access
contain
ntermin
human
signal
peptid
ctermin
tag
express
insect
cell
use
bactobac
express
system
life
technolog
inc
secret
cell
cultur
medium
purifi
sequenti
hitrap
nickel
chelat
hp
column
superdex
gel
filtrat
column
ge
healthcar
sd
gel
electrophoresi
mg
wild
type
mutant
merscov
rbd
subject
sd
gel
electrophoresi
denatur
condit
protein
band
stain
use
coomassi
brilliant
blue
r
sigmaaldrich
imag
captur
use
myecl
imag
life
technolog
inc
mass
spectrometri
wild
type
mutant
merscov
rbd
mm
concentr
mm
triscl
ph
mm
nacl
ultrafiltr
deioniz
water
five
time
use
amicon
ultra
centrifug
filter
kda
molecular
weight
cutoff
desalt
protein
sampl
subject
malditof
mass
spectrometri
tuft
univers
core
facil
mass
spectrometri
perform
linear
mode
molecular
weight
screen
alphascreen
proteinprotein
bind
assay
bind
recombin
merscov
rbd
recombin
human
measur
use
alphascreen
assay
previous
describ
briefli
nm
wild
type
mutant
merscov
rbd
ctermin
fc
tag
incub
nm
human
ctermin
tag
room
temperatur
h
alphascreen
protein
acceptor
bead
nickel
chelat
donor
bead
perkinelm
life
scienc
ad
mixtur
final
concentr
mg
ml
incub
room
temperatur
h
alphascreen
signal
measur
use
enspir
plate
reader
perkinelm
life
scienc
reflect
bind
affin
two
protein
fac
bind
recombin
merscov
rbd
human
express
cellsurfac
measur
use
fluorescenceactiv
cell
sort
fac
previous
describ
briefli
cell
incub
wild
type
mutant
merscov
rbd
mg
ml
room
temperatur
min
follow
addit
fitcconjug
antihumaniggfc
polyclon
antibodi
dilut
sigmaaldrich
min
amount
rbdbound
cell
measur
use
flow
cytometri
bind
affin
rbd
cellsurfac
character
median
fluoresc
intens
anim
immun
sampl
collect
anim
immun
sampl
collect
carri
previous
describ
briefli
balbc
mice
subcutan
immun
wild
type
mutant
merscov
rbd
mg
per
mous
presenc
montanid
adjuv
pb
plu
montanid
includ
neg
control
immun
mice
boost
twice
immunogen
adjuv
interv
sera
collect
day
last
immun
detect
neutral
antibodi
elisa
bind
recombin
merscov
rbd
neutral
mab
measur
use
elisa
previous
describ
briefli
elisa
plate
precoat
amount
wild
type
mutant
rbd
mg
ml
overnight
block
nonfat
milk
h
serial
dilut
mab
ad
plate
incub
h
wash
plate
incub
h
horseradishperoxidaseconjug
antihumaniggfab
polyclon
antibodi
dilut
sigmaaldrich
enzymat
reaction
carri
use
substrat
life
technolog
inc
stop
n
h
absorb
nm
measur
use
elisa
plate
reader
tecan
group
ltd
competit
neutral
mab
mutantrbdinduc
mous
serum
bind
wild
type
merscov
rbd
carri
use
elisa
describ
except
bind
wild
type
rbd
neutral
mab
mg
ml
concentr
perform
presenc
serial
dilut
mous
serum
wildtyperbdinduc
pbsinduc
rbdmab
bind
detect
addit
horseradishperoxidaseconjug
antihumaniggfab
polyclon
antibodi
dilut
subsequ
enzymat
reaction
live
merscov
neutral
assay
microneutr
assay
carri
test
neutral
antibodi
live
merscov
previous
describ
briefli
serial
dilut
mous
sera
incub
room
temperatur
h
infecti
merscov
virion
strain
incub
vero
cell
h
neutral
capabl
mous
sera
measur
determin
presenc
absenc
virusinduc
cytopath
effect
cpe
neutral
antibodi
titr
express
reciproc
highest
dilut
sera
complet
inhibit
virusinduc
cpe
least
well
nt
merscov
challeng
studi
merscov
challeng
studi
carri
use
mice
previous
describ
briefli
mice
intramuscularli
immun
wild
type
mutant
merscov
rbd
mg
per
mous
presenc
aluminium
adjuv
boost
week
initi
immun
week
second
immun
mice
challeng
merscov
strain
tcid
observ
day
detect
surviv
rate
weight
chang
statist
analys
fig
comparison
wt
rbd
mutant
rbd
bind
recombin
alphascreen
fig
cellsurfac
fac
fig
done
use
twotail
ttest
measur
rbd
fig
measur
rbd
fig
fig
nonlinear
regress
perform
use
log
inhibitor
versu
normal
responsevari
slope
model
r
curv
fit
larger
curv
fig
extra
sumofsquar
f
test
differ
dilut
mab
measur
dilut
mab
fig
comparison
wt
rbd
mutant
rbd
capac
induc
neutral
serum
mice
done
use
twotail
ttest
measur
rbd
fig
nonlinear
regress
perform
use
log
inhibitor
versu
normal
responsevari
slope
model
r
curv
fit
larger
curv
fig
comparison
wtrbdinduc
serum
serum
inhibit
rbdmab
bind
elisa
done
use
extra
sumofsquar
f
test
differ
dilut
serum
measur
dilut
serum
statist
analys
perform
use
graphpad
prism
softwar
data
avail
relev
data
avail
author
